(3R,5R)-5-(3-[18F]fluorophenyl)-3-(((R)-1-phenylethyl)amino)-1-(4-(trifluoromethyl)phenyl)pyrrolidin-2-one ([18F]FPATPP) is an inverse agonist radioligand for CB1 receptors of the endocannabinoid system, an analogue of [18F]FMPEP-d2 (Lahdenpohja et al., 2020). [18F]FPATPP is more stable against radiolysis than [18F]FMPEP-d2, with over 300 min shelf life. In preclinical evaluation defluorination is significantly lower, and washout is faster (Lahdenpohja et al., 2020).

Clinical evaluation of [18F]FPATPP is ongoing.

See also:


Horti AG, Raymont V, Terry GE. PET imaging of endocannabinoid system. In: Dierckx RAJO et al. (eds.) PET and SPECT of Neurobiological Systems. Springer, 2014. doi: 10.1007/978-3-642-42014-6_11.

Terry G. In vivo imaging of the cannabinoid CB1 receptor using positron emission tomography. Ph.D. thesis, Karolinska Institutet, Stockholm, 2009. ISBN: 978-91-7409-677-4.

Tags: ,

Updated at: 2022-01-17
Created at: 2022-01-17
Written by: Vesa Oikonen